Search Results
Onco
Daily
Facebook
RSS
X
Youtube
Linkedin
September, 2024
September 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
« Aug
Vivek Subbiah
Nov 13, 2023, 12:58 |
Blog
Vivek Subbiah: Incredible meeting of the Early Phase Drug Development minds
Vivek Subbiah shared on LinkedIn: “Wow! Incredible meeting of the Early Phase Drug Development minds.…
Nov 9, 2023, 23:40 |
Blog
Vivek Subbiah: A study in the United States, Canada, & Germany using retrospective real-world databases
Vivek Subbiah, made the following post on Twitter: "Hot off the press: Pleased to share…
Nov 9, 2023, 19:17 |
Opinion
Vivek Subbiah: Feeling grateful to have a brilliant and forward-thinking global expert in GU as a close friend Neeraj Agarwal
Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, posted the following…
Nov 9, 2023, 18:04 |
Blog
Vivek Subbiah: Zhen, is that pin in your suit for Disney 100?
Vivek Subbiah, Chief of Early-Phase Drug Development at Sarah Cannon Research Institute, shared on LinkedIn:…
Nov 6, 2023, 22:47 |
Blog
Vivek Subbiah: We've been to the moon, now we need to go to Mars and beyond to eradicate cancer
Vivek Subbiah, posted the following on Twitter: What is the best way to spend that extra…
Nov 6, 2023, 03:26 |
Blog
Vivek Subbiah: How to build a successful phase 1 program?
Vivek Subbiah posted the following on X/Twitter: "How to build a successful phase 1 program? -…
Nov 2, 2023, 00:48 |
Blog
Vivek Subbiah: Wow! What an amazing event on “Shaping the future of personalised healthcare for cancer patients”
Vivek Subbiah, posted the following on LinkedIn: "Wow! What an amazing event on 'Shaping the…
Oct 18, 2023, 18:00 |
Drugs
Vivek Subbiah: My perspectives of tumor agnostic drug development
Vivek Subbiah recently shared on LinkedIn: "So honored to present the “Future of Tissue-Agnostic Precision…
Oct 18, 2023, 16:54 |
Drugs
Vivek Subbiah: Final efficacy and safety results of the ROAR phase 2 basket trial of dabrafenib in eight cohorts of patients with BRAFV600E-mutated advanced rare cancers
Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared on…
Oct 17, 2023, 01:32 |
Blog
Vivek Subbiah: Awesome poster presentation on Epha2 targeting by our amazing Dr. Elisa Fontana
Vivek Subbiah shared on LinkedIn: "Kudos to our amazing Sarah Cannon Research Institute Phase 1 clinical…
20
21
22
23
24
All:
326
Posts:
211 - 220
43 Posts Not To Miss From ESMO24 Day 2
45 Posts not to miss from ESMO24 Day 1
OncoDaily Announces Strategic Partnership with the Asian Fund for Cancer Research Limited (AFCR)
Peyo the Therapy Horse: Comforting Terminally Ill Patients Through Horse Therapy.
100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social Media in 2024: Part 3
Special Coverage
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Facebook
RSS Feed
X
Linkedin
Youtube